SRR1436106
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.448
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.439
- XENOBIOTIC_METABOLISM+0.404
- COAGULATION+0.394
- KRAS_SIGNALING_DN+0.382
- INTERFERON_GAMMA_RESPONSE+0.378
- IL6_JAK_STAT3_SIGNALING+0.361
- MYOGENESIS+0.327
- BILE_ACID_METABOLISM+0.317
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.261
Top 10 suppressed
- NOTCH_SIGNALING-0.480
- G2M_CHECKPOINT-0.446
- PROTEIN_SECRETION-0.416
- MYC_TARGETS_V2-0.407
- TGF_BETA_SIGNALING-0.407
- MYC_TARGETS_V1-0.406
- UNFOLDED_PROTEIN_RESPONSE-0.402
- MITOTIC_SPINDLE-0.385
- E2F_TARGETS-0.367
- WNT_BETA_CATENIN_SIGNALING-0.353
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR656167 | GTEX | — | 0.926 |
| 2 | ERR2598280 | fetal | fetal | 0.918 |
| 3 | SRR1471922 | GTEX | — | 0.910 |
| 4 | ERR2598268 | fetal | fetal | 0.905 |
| 5 | ERR2598328 | fetal | fetal | 0.889 |
| 6 | ERR2598269 | fetal | fetal | 0.887 |
| 7 | ERR2598335 | fetal | fetal | 0.876 |
| 8 | SRR1364739 | GTEX | — | 0.873 |
| 9 | ERR2598329 | fetal | fetal | 0.871 |
| 10 | MDT-AP-1254 | Med | Medulloblastoma | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.448 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.439 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.404 | Inavolisib | — uncovered |
| COAGULATION | 0.394 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.382 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.378 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.361 | Inavolisib | — uncovered |
| MYOGENESIS | 0.327 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.317 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.261 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.261 | Idelalisib | — uncovered |
| COMPLEMENT | 0.245 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.238 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.217 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.217 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.215 | Inavolisib | — uncovered |
| HYPOXIA | 0.206 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.194 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.193 | Idelalisib | — uncovered |
| APOPTOSIS | 0.183 | Idelalisib | — uncovered |